tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

NAMS Stock Latest News

Esperion initiated with an Overweight at Cantor Fitzgerald
The FlyEsperion initiated with an Overweight at Cantor Fitzgerald
4d ago
ESPR
NAMS
Menarini announces topline data from Phase 3 BROADAY, TANDEM trials
PremiumThe Fly
Menarini announces topline data from Phase 3 BROADAY, TANDEM trials
5d ago
NAMS
NewAmsterdam Pharma’s $452.6M Public Offering Success
PremiumCompany Announcements
NewAmsterdam Pharma’s $452.6M Public Offering Success
8d ago
8K
NAMS
NewAmsterdam Pharma 12.12M share Secondary priced at $24.50
PremiumThe Fly
NewAmsterdam Pharma 12.12M share Secondary priced at $24.50
9d ago
NAMS
Esperion selloff continues following competitor data from NewAmsterdam
PremiumThe Fly
Esperion selloff continues following competitor data from NewAmsterdam
10d ago
ESPR
NAMS
NewAmsterdam Pharma price target raised to $47 from $35 at Scotiabank
PremiumThe FlyNewAmsterdam Pharma price target raised to $47 from $35 at Scotiabank
10d ago
NAMS
NewAmsterdam Pharma announces $300M offering of ordinary shares, warrants
Premium
The Fly
NewAmsterdam Pharma announces $300M offering of ordinary shares, warrants
10d ago
NAMS
NewAmsterdam Pharma price target raised to $48 from $45 at Leerink
Premium
The Fly
NewAmsterdam Pharma price target raised to $48 from $45 at Leerink
10d ago
NAMS
NewAmsterdam price target raised to $40 from $31 at RBC Capital
PremiumThe Fly
NewAmsterdam price target raised to $40 from $31 at RBC Capital
10d ago
NAMS
Verve Therapeutics has positive read from NewAmsterdam data, says Stifel
PremiumThe Fly
Verve Therapeutics has positive read from NewAmsterdam data, says Stifel
10d ago
NAMS
VERV
Oracle reports mixed Q2, Gen Digital to acquire MoneyLion: Morning Buzz
PremiumThe Fly
Oracle reports mixed Q2, Gen Digital to acquire MoneyLion: Morning Buzz
10d ago
M
AI
NewAmsterdam Pharma Unveils Promising Phase 3 Trial Results
PremiumCompany Announcements
NewAmsterdam Pharma Unveils Promising Phase 3 Trial Results
11d ago
8K
NAMS
NewAmsterdam reports data from Phase 3 BROADWAY trial, met primary endpoint
PremiumThe FlyNewAmsterdam reports data from Phase 3 BROADWAY trial, met primary endpoint
11d ago
NAMS
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
Premium
Company Announcements
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
1M ago
8K
NAMS
NewAmsterdam Pharma’s Promising Phase 3 Trial Results
Premium
Company Announcements
NewAmsterdam Pharma’s Promising Phase 3 Trial Results
1M ago
8K
NAMS
NewAmsterdam Pharma Reports Strong Q3 and Trial Progress
PremiumCompany Announcements
NewAmsterdam Pharma Reports Strong Q3 and Trial Progress
1M ago
NAMS
Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends
PremiumCompany Announcements
Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends
1M ago
NAMS
NewAmsterdam Pharma reports Q3 EPS (18c), consensus (50c)
PremiumThe Fly
NewAmsterdam Pharma reports Q3 EPS (18c), consensus (50c)
1M ago
NAMS
NewAmsterdam Pharma management to meet with Piper Sandler
PremiumThe Fly
NewAmsterdam Pharma management to meet with Piper Sandler
3M ago
NAMS
Piper sees ‘attractive buying opportunity’ into NewAmsterdam data
PremiumThe FlyPiper sees ‘attractive buying opportunity’ into NewAmsterdam data
3M ago
NAMS
NewAmsterdam Pharma initiated with a Buy at Needham
Premium
The Fly
NewAmsterdam Pharma initiated with a Buy at Needham
4M ago
NAMS
NewAmsterdam Pharma management to meet with Jefferies
Premium
The Fly
NewAmsterdam Pharma management to meet with Jefferies
4M ago
NAMS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >